{"url_path":"/sec/nbix/8-k/2026-05-18/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/914475/0001193125-26-228013-index.html","accession_number":"0001193125-26-228013","cik":"0000914475","ticker":"NBIX","issuer_name":"NEUROCRINE BIOSCIENCES INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/914475/0001193125-26-228013-index.html","primary_entity_key":"0000914475","primary_entity_name":"NEUROCRINE BIOSCIENCES INC"},"word_count":156,"has_tables":true,"body_markdown":"Item 7.01.\n\nRegulation FD Disclosure.\n\nOn May 18, 2026, the Company issued a press release announcing the closing of the Merger, a copy of which is attached as Exhibit 99.1 to this Report and incorporated by reference herein.\n\nThe information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and will not be incorporated by reference into any other filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1."}